PerkinElmer’s SIRION Biotech business, providing viral vector-based gene delivery technologies for gene and cell therapy and vaccine development, and the Centre for Genomic Regulation (CRG), an international biomedical research center located in Barcelona, Spain, have entered into an agreement to jointly develop new generation adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy in the pancreas. The collaboration combines SIRION’s AAV technology platform and expertise in viral vector development and production with CRG’s knowledge of genetic regulatory mechanisms. The end goal is to develop AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes under control of cell-specific regulatory elements. This approach seeks to increase the precision, safety, and efficacy of future AAV-based gene therapies for diabetes.